# TRANSFORMATIONAL EPICENTER

---

## Risk Disclosure Document

**Document 17** | Data Room - Legal & Compliance

**Date:** January 2026
**Classification:** RESTRICTED - CONFIDENTIAL
**Version:** 1.0
**Prepared by:** Transformational Epicenter Holdings, LLC

---

> **IMPORTANT NOTICE**
>
> This Risk Disclosure Document is provided to prospective investors as part of
> Transformational Epicenter's investor data room. It is intended to provide a
> comprehensive and transparent assessment of the material risks associated with
> an investment in Transformational Epicenter Holdings, LLC.
>
> Prospective investors should carefully review this document in its entirety
> before making any investment decision. The risks described herein are not
> exhaustive and additional risks not presently known or currently deemed
> immaterial may also adversely affect the Company's business, financial
> condition, and results of operations.

---

## Table of Contents

1. [Forward-Looking Statements Disclaimer](#1-forward-looking-statements-disclaimer)
2. [Risk Summary Dashboard](#2-risk-summary-dashboard)
3. [Detailed Risk Analysis](#3-detailed-risk-analysis)
4. [Risk Matrix](#4-risk-matrix)
5. [Risk Monitoring and Management](#5-risk-monitoring-and-management)
6. [Forward-Looking Statements](#6-forward-looking-statements)
7. [Confidentiality Notice](#7-confidentiality-notice)

---

## 1. Forward-Looking Statements Disclaimer

This document contains forward-looking statements within the meaning of applicable securities laws. Forward-looking statements include, but are not limited to, statements regarding the Company's plans, objectives, expectations, and intentions, as well as statements regarding future financial performance, growth strategies, and market opportunities.

Forward-looking statements are based on the Company's current expectations and assumptions about future events. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements.

The risks identified in this document are based on management's current assessment and are subject to change as the business environment evolves. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

**Prospective investors are cautioned not to place undue reliance on forward-looking statements.**

---

## 2. Risk Summary Dashboard

### 2.1 Risk Overview

| Metric | Count |
|--------|-------|
| **High Severity Risks** | 3 |
| **Medium Severity Risks** | 5 |
| **Total Risk Categories** | 8 |
| **Total Mitigation Strategies** | 42 |

### 2.2 Risk Summary Table

| # | Risk Category | Severity | Likelihood | Mitigation Count |
|---|--------------|----------|------------|-----------------|
| 1 | Regulatory Risk | High | Low | 5 |
| 2 | Medical Risk | High | Low | 6 |
| 3 | Reputation Risk | High | Medium | 5 |
| 4 | Competition Risk | Medium | High | 5 |
| 5 | Execution Risk | Medium | Medium | 5 |
| 6 | Key Person Risk | Medium | Medium | 5 |
| 7 | Market Risk | Medium | Low | 5 |
| 8 | Financial Risk | Medium | Low | 6 |
| | **TOTAL** | | | **42** |

### 2.3 Risk Distribution

```
    SEVERITY DISTRIBUTION          LIKELIHOOD DISTRIBUTION

    High:   3 risks (37.5%)        High:   1 risk  (12.5%)
    Medium: 5 risks (62.5%)        Medium: 3 risks (37.5%)
    Low:    0 risks  (0.0%)        Low:    4 risks (50.0%)
```

---

## 3. Detailed Risk Analysis

---

### 3.1 Regulatory Risk

**Severity: HIGH | Likelihood: LOW**

**Description:**
Changes to Mexican federal or state law regarding ibogaine, psychedelic substances, or healthcare facility regulations could materially impact the Company's ability to operate its core treatment programs. While ibogaine is currently unscheduled in Mexico, the regulatory environment for psychedelic substances is evolving globally, and there can be no assurance that the current legal status will remain unchanged.

**Specific Risk Factors:**

- Reclassification of ibogaine as a controlled substance in Mexico
- New COFEPRIS regulations creating additional licensing burdens
- Changes to Mexico's General Health Law affecting healthcare facility requirements
- International treaty obligations that could influence Mexican drug scheduling
- State-level regulations in Quintana Roo restricting specific medical practices
- Changes to foreign investment rules affecting healthcare sector ownership

**Mitigation Strategies:**

| # | Strategy | Description |
|---|----------|-------------|
| 1 | Medical-Grade Operations | Operate under full medical supervision with hospital-grade protocols, positioning the facility as a legitimate medical institution rather than a recreational or underground operation. Medical credibility provides regulatory defensibility. |
| 2 | Health Authority Relationships | Establish and maintain proactive relationships with COFEPRIS, state health authorities, and relevant regulatory bodies. Participate in public comment periods and regulatory consultations. Engage former regulators as advisors. |
| 3 | Geographic Diversification | Maintain expansion optionality across multiple jurisdictions (see expansion research). If one jurisdiction restricts operations, the Company can pivot to alternative locations with favorable legal frameworks. |
| 4 | Legal Monitoring Program | Retain psychedelic policy counsel to continuously monitor legislative developments at federal, state, and international levels. Maintain early warning system for regulatory changes with 12-18 month horizon. |
| 5 | Clinical Best Practices | Adopt and exceed the highest international standards for ibogaine-assisted therapy, including published clinical guidelines and peer-reviewed protocols. Compliance with emerging standards positions the Company favorably under any future regulatory framework. |

**Residual Risk After Mitigation:** Low-to-Medium. While regulatory risk cannot be eliminated, the combination of medical-grade operations, regulatory relationships, geographic diversification, and proactive monitoring significantly reduces the likelihood and impact of adverse regulatory changes.

---

### 3.2 Medical Risk

**Severity: HIGH | Likelihood: LOW**

**Description:**
Ibogaine carries known medical risks, most significantly cardiac complications (QT interval prolongation, arrhythmias). Adverse medical events during treatment could result in patient harm, malpractice liability, regulatory scrutiny, and reputational damage. The Company administers a substance with a narrow therapeutic-to-toxic ratio in a setting where patients may have complex medical histories.

**Specific Risk Factors:**

- Cardiac events during ibogaine administration (QT prolongation, torsades de pointes)
- Adverse drug interactions with undisclosed medications
- Psychological distress or psychiatric emergencies during treatment
- Allergic or idiosyncratic reactions
- Medical complications during recovery period
- Errors in screening, dosing, or monitoring

**Mitigation Strategies:**

| # | Strategy | Description |
|---|----------|-------------|
| 1 | Comprehensive Cardiac Screening | All patients undergo pre-treatment cardiac evaluation including 12-lead ECG, QTc interval measurement, cardiac history review, and medication interaction analysis. Patients with elevated cardiac risk are excluded. |
| 2 | Continuous Medical Monitoring | Real-time cardiac telemetry monitoring throughout the ibogaine treatment window (minimum 36 hours). Vital signs (heart rate, blood pressure, oxygen saturation, temperature) monitored continuously with automated alerts for parameter deviations. |
| 3 | 24/7 Physician Presence | Board-certified physicians on-site at all times during active treatment periods. Physician-to-patient ratio maintained at levels exceeding standard clinical requirements. Shift schedules ensure no fatigue-related errors. |
| 4 | Emergency Response Protocols | Comprehensive emergency response capability including ACLS-trained staff, crash cart with defibrillator, emergency cardiac medications, supplemental oxygen, and established relationship with Galenia Hospital in Cancun for emergency evacuation if needed. |
| 5 | Strict Exclusion Criteria | Detailed medical exclusion criteria that eliminate patients with elevated risk profiles: cardiac conditions, contraindicated medications (SSRIs, MAOIs, antiarrhythmics), hepatic impairment, psychiatric instability, active substance use, and other risk factors identified in clinical literature. |
| 6 | Medical Malpractice Insurance | Comprehensive medical malpractice insurance policy ($5M per occurrence / $15M aggregate) obtained from a carrier experienced in alternative/integrative medicine coverage. Policy covers all clinical staff and treatment modalities. |

**Residual Risk After Mitigation:** Low. The combination of rigorous screening, continuous monitoring, physician presence, emergency capability, and strict exclusion criteria reduces the probability of serious adverse events to a level comparable with established interventional medical procedures.

---

### 3.3 Reputation Risk

**Severity: HIGH | Likelihood: MEDIUM**

**Description:**
The Company operates at the intersection of luxury hospitality, medical services, and psychedelic medicine -- a combination that carries reputational sensitivity. Negative media coverage, patient complaints, association with the underground psychedelic scene, or adverse incidents could damage the Company's brand, reduce referral partnerships, and impair the ability to attract high-value clientele.

**Specific Risk Factors:**

- Negative investigative journalism or media coverage of ibogaine facilities
- Patient dissatisfaction or public complaints on review platforms
- Association with underground, unregulated, or unsafe ibogaine providers
- Social media amplification of negative experiences
- Regulatory enforcement actions becoming public record
- Celebrity or public figure adverse experience generating media attention

**Mitigation Strategies:**

| # | Strategy | Description |
|---|----------|-------------|
| 1 | Medical-Grade Positioning | Brand and position the facility as a medical institution first, differentiating from retreat centers, ceremonial spaces, and underground providers. Clinical credibility is the primary brand defense. Use language aligned with evidence-based medicine. |
| 2 | Rigorous Patient Selection | Careful patient screening not only for medical appropriateness but also for program fit. Patients who are not good candidates (unrealistic expectations, combative attitude, seeking recreational experience) are respectfully declined. Quality of patient experience starts with patient selection. |
| 3 | Comprehensive Consent Process | Thorough informed consent that sets appropriate expectations, clearly communicates risks and limitations, and ensures patients understand the treatment journey. Under-promising and over-delivering is the goal. Consent process documented and retained. |
| 4 | Proactive Public Relations | Retained PR firm with healthcare and hospitality expertise to manage media relations, develop positive narrative, respond to negative coverage, and build relationships with responsible journalists. Proactive earned media strategy. |
| 5 | Research Institution Relationships | Establish partnerships with academic research institutions for clinical outcome tracking, publish results in peer-reviewed journals, and contribute to the scientific evidence base. Academic affiliations provide third-party credibility and media counterweight. |

**Residual Risk After Mitigation:** Medium. Reputation risk can be managed but not eliminated. The mitigation strategies significantly reduce the probability and impact of reputational damage, but operating in a sensitive sector means some residual reputation risk is inherent.

---

### 3.4 Competition Risk

**Severity: MEDIUM | Likelihood: HIGH**

**Description:**
The luxury wellness, medical tourism, and psychedelic therapy sectors are experiencing rapid growth, attracting new entrants and increasing competition. Established healthcare organizations, luxury hospitality brands, and well-funded startups may enter the market with superior resources. Additionally, potential U.S. legalization of psychedelic therapy could reduce the need for patients to travel internationally.

**Specific Risk Factors:**

- New ibogaine clinics opening in Mexico and other jurisdictions
- Established luxury rehabilitation centers adding psychedelic modalities
- Hospital systems or academic medical centers launching psychedelic programs
- U.S. FDA approval of psychedelic-assisted therapy reducing medical tourism demand
- Well-funded competitors with lower pricing or superior marketing
- Technology companies creating telemedicine alternatives for preparation/integration

**Mitigation Strategies:**

| # | Strategy | Description |
|---|----------|-------------|
| 1 | First-Mover Advantage | Establish market leadership in the luxury medical ibogaine space before the sector matures. Build brand recognition, develop referral networks, and accumulate clinical outcome data that create barriers to entry for later entrants. |
| 2 | Brand Equity and Loyalty | Invest heavily in guest experience, clinical outcomes, and post-treatment support to build a reputation that competitors cannot easily replicate. Target Net Promoter Score above 80. Guest referrals and repeat visits create organic growth moat. |
| 3 | Proprietary Clinical Protocols | Develop and document proprietary treatment protocols, screening algorithms, dosing frameworks, and integration programs that represent intellectual property and competitive differentiation. Publish research demonstrating superior outcomes. |
| 4 | Location Premium | The Riviera Maya location offers a unique combination of natural beauty, accessibility from the U.S., favorable legal environment, and lower operating costs. This location premium is difficult for U.S.-based competitors to replicate even with domestic legalization. |
| 5 | Expansion Optionality | Maintain a pipeline of potential expansion locations (30 markets analyzed in expansion research). Ability to expand into new geographies as market develops provides strategic optionality that single-location competitors lack. |

**Residual Risk After Mitigation:** Medium. Competition is an inherent feature of attractive markets. The mitigation strategies create meaningful competitive advantages, but the Company must continue to innovate and invest in differentiation.

---

### 3.5 Execution Risk

**Severity: MEDIUM | Likelihood: MEDIUM**

**Description:**
Successfully launching Transformational Epicenter requires executing across multiple complex workstreams: property acquisition, facility renovation, regulatory licensing, medical team recruitment, hospitality operations, and technology platform development. Delays, cost overruns, or quality issues in any workstream could delay revenue generation and increase capital requirements.

**Specific Risk Factors:**

- Property acquisition delays or unfavorable terms
- Renovation cost overruns or timeline delays
- Difficulty recruiting qualified Mexican-licensed medical staff
- COFEPRIS licensing delays extending pre-revenue period
- Occupancy ramp-up slower than projected
- Technology platform development delays
- Supply chain issues for medical equipment or specialty items

**Mitigation Strategies:**

| # | Strategy | Description |
|---|----------|-------------|
| 1 | Experienced Local Partners | Engage experienced Mexican real estate counsel, construction managers, and regulatory consultants who have completed similar projects in Quintana Roo. Local expertise reduces learning-curve delays and avoids common foreign-investor mistakes. |
| 2 | Conservative Budget with Contingency | All financial projections include a 15% contingency buffer on capital expenditures and a conservative revenue ramp-up schedule. Budget assumptions are stress-tested against historical renovation and hospitality launch data for the region. |
| 3 | Phased Ramp-Up Strategy | Launch with a smaller initial capacity and scale operations as demand materializes and processes are validated. This phased approach reduces upfront capital requirements and allows iterative improvement before full-scale operations. |
| 4 | Multiple Property Options | Evaluate multiple property candidates simultaneously. If the primary target falls through, alternative properties are identified and can be pursued without restarting the search process from zero. |
| 5 | Hospitality Industry Advisors | Retain advisors with specific experience launching luxury hospitality operations in the Riviera Maya region. Their operational playbooks, vendor relationships, and staffing networks accelerate the launch timeline. |

**Residual Risk After Mitigation:** Low-to-Medium. Execution risk is manageable with experienced partners, conservative planning, and phased deployment. The primary mitigant is realistic planning with adequate contingency rather than aggressive timelines.

---

### 3.6 Key Person Risk

**Severity: MEDIUM | Likelihood: MEDIUM**

**Description:**
The Company's success depends significantly on its founder and a small number of key personnel. The loss or incapacitation of the founder or key clinical staff could disrupt operations, damage investor confidence, and delay business development.

**Specific Risk Factors:**

- Founder departure, illness, or incapacity
- Medical Director resignation or loss of license
- Departure of key clinical staff with specialized training
- Inability to attract qualified replacement personnel
- Knowledge concentration in a small number of individuals
- Burnout or performance degradation of overextended leadership

**Mitigation Strategies:**

| # | Strategy | Description |
|---|----------|-------------|
| 1 | Deep Leadership Bench | Recruit and develop a leadership team with overlapping capabilities. No single individual should be the sole repository of critical knowledge or relationships. Cross-training and succession planning begin at launch. |
| 2 | Documented Protocols and SOPs | All clinical protocols, operational procedures, vendor relationships, and institutional knowledge are documented in comprehensive Standard Operating Procedures. Documentation ensures continuity regardless of personnel changes. |
| 3 | Key Person Insurance | Obtain key person life and disability insurance policies on the founder and critical personnel. Insurance proceeds provide capital to fund recruitment and transition if a key person is lost. |
| 4 | Equity Incentive Program | Implement a meaningful equity incentive program (ESOP or profit interests) for key employees to align long-term interests and reduce voluntary turnover. Vesting schedules encourage retention through critical growth periods. |
| 5 | Advisory Board | Establish an advisory board of experienced operators, medical professionals, and industry experts who can provide continuity of guidance and institutional knowledge independent of any single team member. |

**Residual Risk After Mitigation:** Low-to-Medium. Key person risk cannot be fully eliminated in an early-stage company, but documentation, insurance, incentive alignment, and team depth meaningfully reduce the impact of personnel changes.

---

### 3.7 Market Risk

**Severity: MEDIUM | Likelihood: LOW**

**Description:**
The Company's revenue projections assume sustained demand for luxury medical wellness and ibogaine-assisted therapy. Macroeconomic downturns, changes in insurance coverage, shifts in treatment preferences, or negative publicity about ibogaine therapy generally could reduce demand below projected levels.

**Specific Risk Factors:**

- Economic recession reducing discretionary healthcare spending
- Health insurance changes affecting out-of-pocket willingness to pay
- Shifts in consumer preference away from psychedelic-assisted therapy
- Negative clinical research findings regarding ibogaine efficacy or safety
- Geopolitical events reducing international travel to Mexico
- Currency fluctuations affecting pricing competitiveness

**Mitigation Strategies:**

| # | Strategy | Description |
|---|----------|-------------|
| 1 | Multiple Revenue Segments | Diversify revenue across multiple service lines: ibogaine therapy, bio-optimization, medical longevity, luxury wellness retreats, and executive health programs. Reduces dependence on any single treatment modality. |
| 2 | Premium Positioning | Target the upper end of the market where spending is less cyclical and less sensitive to economic downturns. Ultra-high-net-worth individuals and executive clients maintain wellness spending through economic cycles. |
| 3 | Recurring Revenue Model | Design program structures that encourage repeat visits: quarterly bio-optimization check-ups, annual longevity assessments, and ongoing integration support. Recurring revenue provides stability during demand fluctuations. |
| 4 | Diversified Referral Network | Build referral relationships across multiple channels: concierge physicians, executive health programs, addiction specialists, performance coaches, family offices, and direct consumer marketing. No single referral source should represent more than 15% of patients. |
| 5 | Flexible Pricing Architecture | Maintain pricing flexibility to adjust to market conditions: tiered program options, seasonal promotions, corporate partnership rates, and financing arrangements. Flexibility allows demand capture across economic conditions. |

**Residual Risk After Mitigation:** Low. The combination of multiple revenue segments, premium positioning, recurring revenue, diversified referrals, and pricing flexibility creates resilience against market fluctuations. The target demographic is inherently less price-sensitive than the general population.

---

### 3.8 Financial Risk

**Severity: MEDIUM | Likelihood: LOW**

**Description:**
The Company is a pre-revenue startup requiring significant capital investment for property acquisition, renovation, licensing, and operational launch. Financial risks include cost overruns exceeding available capital, slower-than-projected revenue ramp-up, unforeseen expenses, currency exchange fluctuations, and the potential need for additional capital raises on dilutive terms.

**Specific Risk Factors:**

- Capital expenditure overruns exceeding contingency budget
- Revenue ramp-up slower than financial model projections
- Unforeseen regulatory costs or compliance expenses
- Mexican peso / U.S. dollar exchange rate fluctuations
- Need for bridge financing or additional capital at unfavorable terms
- Working capital shortfall during pre-profitability period
- Tax obligations exceeding projected amounts

**Mitigation Strategies:**

| # | Strategy | Description |
|---|----------|-------------|
| 1 | Conservative Financial Projections | All financial models use conservative assumptions: lower occupancy rates, higher cost estimates, and longer ramp-up timelines than industry benchmarks. Best-case scenarios are not used for capital planning. |
| 2 | 15% Capital Contingency | A 15% contingency is included in all capital budgets to absorb cost overruns without requiring additional capital raises. This contingency is separate from operating reserves. |
| 3 | Phased Capital Investment | Capital is deployed in phases aligned with milestones and validation of key assumptions. Not all capital is committed upfront; later phases are contingent on earlier phases meeting performance targets. |
| 4 | Operating Reserves | Minimum 6 months of operating expenses maintained in reserve from initial capital raise. Reserves provide runway for slower-than-projected revenue ramp-up without triggering a capital emergency. |
| 5 | Milestone-Based Capital Deployment | Investor capital is deployed against defined milestones (property acquisition, renovation completion, license obtained, first patient). Milestone-based deployment provides natural checkpoints for capital efficiency. |
| 6 | Currency Hedging Strategy | Implement basic currency hedging for significant MXN/USD exposures. Revenue is primarily in USD while major costs are in MXN, providing a natural hedge. Formal hedging instruments used for large, fixed MXN-denominated obligations. |

**Residual Risk After Mitigation:** Low. Conservative projections, adequate contingency, phased deployment, and operating reserves create multiple layers of financial protection. The primary financial risk is managed through disciplined capital allocation rather than aggressive growth assumptions.

---

## 4. Risk Matrix

### 4.1 Risk Heat Map

```
                            RISK MATRIX
    ┌─────────────────────────────────────────────────────────┐
    │                                                         │
    │  SEVERITY                                               │
    │                                                         │
    │  HIGH    │ [1] Regulatory  │                │           │
    │          │ [2] Medical     │ [3] Reputation │           │
    │          │                 │                │           │
    │  --------├-----------------├----------------├-----------│
    │          │                 │                │           │
    │  MEDIUM  │ [7] Market      │ [5] Execution  │ [4] Comp- │
    │          │ [8] Financial   │ [6] Key Person │  etition  │
    │          │                 │                │           │
    │  --------├-----------------├----------------├-----------│
    │          │                 │                │           │
    │  LOW     │                 │                │           │
    │          │                 │                │           │
    │  --------├-────────────────├────────────────├───────────│
    │          │      LOW        │    MEDIUM      │   HIGH    │
    │          │                 │                │           │
    │          │            LIKELIHOOD                        │
    └─────────────────────────────────────────────────────────┘
```

### 4.2 Risk Priority Ranking

| Priority | Risk Category | Combined Score | Action Required |
|----------|--------------|---------------|-----------------|
| 1 | Reputation Risk | High Severity / Medium Likelihood | Active management; ongoing monitoring |
| 2 | Medical Risk | High Severity / Low Likelihood | Protocols in place; continuous improvement |
| 3 | Regulatory Risk | High Severity / Low Likelihood | Monitoring program; contingency planning |
| 4 | Competition Risk | Medium Severity / High Likelihood | Strategic differentiation; market intelligence |
| 5 | Execution Risk | Medium Severity / Medium Likelihood | Project management; partner selection |
| 6 | Key Person Risk | Medium Severity / Medium Likelihood | Team building; documentation; insurance |
| 7 | Market Risk | Medium Severity / Low Likelihood | Revenue diversification; premium positioning |
| 8 | Financial Risk | Medium Severity / Low Likelihood | Conservative planning; reserve management |

### 4.3 Aggregate Risk Assessment

The overall risk profile of Transformational Epicenter is **moderate**, consistent with an early-stage venture in a rapidly growing market at the intersection of healthcare, hospitality, and emerging therapeutic modalities. The three highest-severity risks (regulatory, medical, reputation) all have identified and implementable mitigation strategies that reduce residual risk to manageable levels.

The Company's risk management approach emphasizes:

- **Medical-grade operations** as the foundation of regulatory and reputational defense
- **Conservative financial planning** with multiple contingency layers
- **Geographic and revenue diversification** to reduce concentration risks
- **Proactive monitoring** of regulatory and competitive developments
- **Team depth and documentation** to reduce key person dependency

No risk identified in this document is assessed as having both high severity and high likelihood. The most significant combined risk (Reputation Risk: High Severity / Medium Likelihood) is manageable through proactive brand positioning, patient selection, and public relations management.

---

## 5. Risk Monitoring and Management

### 5.1 Risk Governance

| Role | Responsibility |
|------|---------------|
| Board of Managers | Quarterly risk review; approval of risk management policies |
| CEO / Founder | Day-to-day risk oversight; risk escalation decisions |
| Medical Director | Clinical risk management; adverse event reporting |
| Legal Counsel | Regulatory risk monitoring; compliance verification |
| CFO / Financial Advisor | Financial risk monitoring; reserve management |

### 5.2 Risk Review Cadence

| Activity | Frequency |
|----------|-----------|
| Comprehensive risk assessment update | Quarterly |
| Regulatory environment scan | Monthly |
| Financial risk indicators review | Monthly |
| Clinical safety metrics review | Weekly |
| Incident reporting and analysis | As needed |
| Board risk briefing | Quarterly |

### 5.3 Key Risk Indicators (KRIs)

The Company will monitor the following Key Risk Indicators:

**Regulatory KRIs:**

- Legislative proposals affecting ibogaine or psychedelics (any jurisdiction)
- COFEPRIS guidance changes or enforcement actions in sector
- Inspection findings and remediation status

**Medical KRIs:**

- Adverse event rate (target: below industry benchmark)
- Patient screening exclusion rate
- Emergency transfer rate
- Patient satisfaction scores

**Financial KRIs:**

- Cash burn rate vs. budget
- Revenue vs. forecast variance
- Operating reserve months remaining
- Capital expenditure vs. budget

**Operational KRIs:**

- Occupancy rate vs. target
- Staff turnover rate
- Regulatory compliance audit scores
- Net Promoter Score

---

## 6. Forward-Looking Statements

This Risk Disclosure Document contains forward-looking statements regarding the Company's planned operations, risk management strategies, financial projections, and business prospects. These statements are based on current expectations, estimates, and projections about the Company's industry, management's beliefs, and certain assumptions made by management.

Forward-looking statements are not guarantees of future performance and involve risks and uncertainties. Actual results may differ materially from those anticipated in the forward-looking statements due to, among other things, the risks described in this document and other factors beyond the Company's control.

The Company expressly disclaims any obligation to update or revise any forward-looking statements contained herein to reflect events or circumstances that occur after the date of this document or to reflect the occurrence of unanticipated events.

**This document does not constitute an offer to sell or a solicitation of an offer to buy any securities. Any such offer will be made only pursuant to a formal offering document that complies with applicable securities laws.**

---

## 7. Confidentiality Notice

This Risk Disclosure Document is confidential and proprietary to Transformational Epicenter Holdings, LLC. It is provided solely to prospective investors and their authorized advisors for the purpose of evaluating a potential investment in the Company.

This document may not be reproduced, distributed, or disclosed to any third party without the prior written consent of Transformational Epicenter Holdings, LLC. By accepting this document, the recipient agrees to maintain its confidentiality and to return or destroy all copies upon request.

The information contained herein is provided "as is" without warranty of any kind, express or implied. The Company makes no representation or warranty as to the accuracy, completeness, or timeliness of the information contained in this document. Prospective investors should conduct their own due diligence and consult their own legal, tax, and financial advisors before making any investment decision.

---

**Document Status:** Active
**Last Updated:** January 2026
**Owner:** Transformational Epicenter Holdings, LLC
**Distribution:** RESTRICTED - CONFIDENTIAL - Authorized prospective investors and advisors only

---

*This Risk Disclosure Document is part of the Transformational Epicenter investor data room (Document 17 of the Legal & Compliance section). It should be read in conjunction with all other data room materials, including the Corporate Structure Overview (Document 14), Mexican Healthcare Regulations (Document 15), and Fideicomiso Trust Structure (Document 16).*
